Daclizumab biosimilar - Sunshine Guojian Pharmaceutical

Drug Profile

Daclizumab biosimilar - Sunshine Guojian Pharmaceutical

Alternative Names: Interleukin-2 receptor antagonist - Sunshine Guojian Pharmaceutical; Xenopax

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Developer Sunshine Guojian Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • No development reported Multiple sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-sclerosis in China (IV, Injection)
  • 01 Jan 2012 Clinical trials in Multiple sclerosis in China (IV)
  • 31 Dec 2011 Launched for Rheumatoid arthritis (prevention) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top